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Summary A new cancer-associated antigen CA130, recognised by two monoclonal antibodies (moABs)
130-22 and 145-9, was often found to be present at high levels in the sera of patients with ovarian cancer.
There was a strong correlation between CA130 and CA125 values. The epitopes recognised by moABs 130-22
and 145-9 were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. Unlike
OC125, the majority of 130-22/145-9 activity was associated with a much lower molecular mass (less than
200 kDa), indicating that a lower molecular mass immunoreactive determination may be a unique CA130
antigenic determinant within CA125 molecule. Clinical data demonstrate that, (1) elevated levels of CA130
determinant were found in the sera of 91.3% of women with epithelial ovarian cancer, (2) falling or rising
levels of CA130 correlated with regression or progression of ovarian cancer in >95% of cases, (3) normalisa-
tion of serum CA130 levels at response does not imply no microscopic residual disease, but CA130 changes
during follow-up support the evaluation of recurrence and can be used as a monitoring marker in an
individual patient.
Monoclonal antibodies (moAbs) that recognise the carbohy-
drate structures of cell-surface glycoproteins and glycolipids
of cancer cells have been regarded as useful tools for charac-
terising cell types and for cancer diagnosis through assaying
of antigenic glycoconjugates secreted into the bloodstream
and as assessed from immunohistochemical studies (Herlyn et
al., 1982; Springer, 1984). Cell surface glycoconjugates, the
composition of which has been shown to change during
tumorigenesis, participate in a biological function
(Hakomori, 1985; Springer et al., 1986; Itzkowitz et al.,
1989). The quantitative and qualitative changes in glycocon-
jugates on cancer cell surfaces are still under investigation
(Itzkowitz et al., 1990; Kobayashi et al., 1991).
The murine moAB OC125 recognises the antigen CA125,
expressed in over 80% of nonmucinous human ovarian
cancers (Bast et al., 1981; Bast et al., 1983; Niloff et al., 1984;
Klug et al., 1984; Kuzuya et al., 1986; Zanaboni et al., 1987).
CA125 has by far been the most useful antigen for detecting
and following-up patients with ovarian cancer (Bast et al.,
1983; Canney et al., 1984; Schilthuis et al., 1987; Vergote et
al., 1987). However, the weak point of this antigen is its
relatively low frequency in mucinous-type ovarian cancers
and its high false-positive rate especially in patients with
endometriosis (Pittaway & Feyez, 1986).
New moAB 130-22 recognising a glycoprotein have been
made by Matsuoka et al. (1987). CA130 is a glycoprotein
recognised by moABs, 130-22 and 145-9, produced by
immunisation with human lung adenocarcinoma cell line PC-
9. The correlation coefficient between the serum levels of
CA130 and CA125 in patients with lung cancer was reported
to be 0.8034 (Matsubara et al., 1989). Also, serum CA130
levels in gynaecologic disease were closely correlated with
serum CA125 levels, demonstrating quite a high correlation
coefficient (r = 0.965) (Inaba et al., 1989).
Clinical evaluation of CA130 antigen has been carried out
in our hospital. Follow-up studies in some patients showed
that CA130 could be useful in monitoring the clinical course
of disease after treatment. The value of CA130 in serum as a
follow-up marker in ovarian cancer has been pointed out but
not yet fully evaluated. This article describes characterisation
of the epitopes recognised by the moABs 130-22 and 145-9.
The clinical evaluation of CA130 as a tumour marker was
investigated by comparison with CA125 in patients with
epithelial ovarian cancer and in those with benign
gynaecologic disease. The second aim is to evaluate CA130
as a follow-up marker in the treatment of ovarian cancer.
Materials and methods
Materials
Murine moABs OC125 and 130-22/145-9 were donated by
Toray Fuji Bionics Co. (Tokyo, Japan) and Daiichi
Radioisotope Co. (Tokyo), respectively. All other reagents
were of analytical grade.
Cell culture
SHIN-3 cells, established from a patient diagnosed as having
serous cystadenocarcinoma of the ovary, were donated by Dr
Y. Kiyozuka (Department of Obstetrics and Gynaecology,
Kurume University, Japan). SHIN-3 cells produced the maxi-
mum amount of CA125 antigen during the growth phase.
The production rate of 1 x 106 cells seeded in a 75-cm2 flask
was, reportedly, 75 U mlh'wk-' (Imai et al., 1989; Imai et
al., 1990). Another cell line, designated as HOC-I, was estab-
lished from a recurrent region of ovarian endometrioid car-
cinoma (Fujii, 1989). The HOC-I cells were grown in RPMI
1640 containing 10% foetal calf serum (FCS). 1 x 106 cells
were seeded in 5 ml medium containing 10% FCS. The pro-
duction rate of CA125 antigen was approximately 1,700 U
ml-' 4 days. To investigate the characteristic of the antigenic
determinant of CA130 antigen, the condition media (CM)
from two ovarian cancer cell lines were used as the source of
CA125 antigen. Pooled culture supernatants were stored at
-20°C.
Purification ofCA125 antigen
CA125 antigen was purified from the CM of HOC-I ovarian
cancer cells according to the method of Davis, H.M. et al.
(Davis et al., 1986). In brief, pooled CM were filtered and
concentrated in an Amicon filter apparatus with a molecular
mass cutoff of 30 kDa (Centricon-30). The concentrated CM
was subjected to perchloric acid precipitation (0.6 M), then
the acid-soluble fraction was neutralised (IN NaOH) and
dialysed against water. This sample was applied on a Sepha-
cryl S-300 column, as described previusly (Matsuoka et al.,
1987). The fraction containing CA125 activity (void volume)
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were pooled, dialysed and then concentrated. The sample was
treated with urea (6M, 30 min, 45°C) to disaggregate the
high-molecular-mass CA125 molecule, and further fractiona-
tion was accomplished by subsequent chromatography on a
Sepharose 6B column equilibrated in 50 mM Tris, 6 M urea,
0.1% SDS (pH 8.0). Majority of the CA125 activity was
associated with a polydisperse molecular mass of 50 kDa to
more than 200 kDa. The fractions containing CA125 activity
with molecular mass of equal or greater than 200 kDa
(CA125 > 200 kDa) and that of less than 200 kDa (CA125
<200 kDa) were separately pooled and concentrated. Protein
concentration was determined by Lowry's method (1951).
Reactivity ofmonoclonal antibodies with cancer cell extracts
To investigate the characteristic of the CAI30 antigen, a
competitive inhibition assay was performed. For competition
enzyme-linked immunosorbent assay (ELISA), supernatants
of sonicated SHIN-3 or HOC-I cells (cancer cell extracts)
were coated on a 96 well microtiter plate (Costar, Cam-
bridge, MA) (16 h, 4C). Increasing concentrations of moABs
(0-8.0 tgml-') were added to each well (1 h, 23°C). After
seven washes, biotin-conjugated second antibody (1.5tLgml',
DAKO) was added to each well (1 h, 23°C), followed by
incubation with avidin-peroxidase (0.4;Lgml-', DAKO; 1 h,
23°C). After three washes, wells were incubated with enzyme
substrate (3.3'-5.5' tetramethylbenzidine/ml dimethylsulfox-
ide) and the absorption was measured in an EIA reader
(Model 2550, Bio-Rad, Richmond, California) at 450 nm.
Reactivity ofmonoclonal antibodies with trypsin-treated cancer
cell extracts
The microtiter plate was coated with supernatants of
sonicated SHIN-3 or HOC-I cells. Each plate was treated
with 0.1% trypsin (1 h, 37°C; Sigma). After washing, the
reactivity of moABs was investigated as described above.
Reaction ofseveral sources ofCA125 antigen with monoclonal
antibodies
Specificity of each moAB (OC125, 130-22 or 145-9) to HOC-
I cell extracts were determined by measuring their ability to
inhibit the bindings of moAB by different sources of CA125
antigens. Endometriotic cyst fluid, menstrual blood, amniotic
fluid, meconium supernatant (as a negative control), CM
from SHIN-3 and HOC-I (crude CA125 antigen), CA125
antigen purified from CM of HOC-I, CA125 >200 kDa, and
CA125 <200 kDa were used as competitors. To determine if
CA125 antigens are involved in the reactivity to moABs, the
inhibitory activities of these antigens were assayed. After
preincubation ofcompetitors and each moAB (1 h, 23°C), the
reaction mixture was transferred to microtiter plates coated
with HOC-I cell extracts (1 h, 23°C). Thereafter, the pro-
cedure was as described above. 1.3 ig ml ' of each moAB
was used for inhibition assays.
In addition, 96 well microtiter plates coated with
1.0 Lgml-' immobilised antibody (OC125 or 130-22) were
incubated with undiluted serum of patient with ovarian
cancer (serum CA125 level= 650 Uml-', 100p1d, 3 h, 23°C).
After five washes, horseradish peroxidase (HRP)-labeled
antibody (HRP-OC125 or HRP-145-9) was incubated to-
gether with OC125, 130-22, or 145-9 (0-8pjgml-'), respec-
tively, as a competitor (3 h, 23°C). The enzyme reaction was
performed.
Patient characteristics and serum samples
Serum samples that had been randomly drawn from 126
patients with epithelial ovarian cancer during the period 1985
through 1991 and from 397 women who were healthy, or
possessed benign gynaecologic diseases were obtained from a
bank of sera preserved at the Department of Gynaecology,
Hamamatsu University School of Medicine, Shizuoka, Japan
(Table I). Blood collection was performed within protocols
approved by the members of the Gynaecological Cancer
Committee of this institute. All patients diagnosed at the
Department of Gynaecology, Hamamatsu University hospital
and its related hospitals entered the study. In all of the study
patients the diagnosis was verified histopathologically. the
age of the patients with ovarian cancer at diagnosis ranged
from 34 to 73 years (mean age, 58 years). Staging of ovarian
cancer according to the FIGO classification showed 45
patients with stage I disease, 20 with stage II, and 61 with
stage III. Classified according to histologic type, 69 patients
had serous adenocarcinomas, 35 had mucinous adenocar-
cinoma, ten had clear cell carcinoma, and 12 had endometrioid
carcinoma. All patients initially underwent cytoreductive sur-
gery and were treated with five cycles of combination
chemotherapy including cisplatin 50 mg m-2, adriamycin
50 mg m-2, and cyclophosphamide 500 mg m-2 (PAC). The
study comprises 119 patients whose residual tumour of 2 cm
or less in size after primary surgery. Women who did not
receive second look operation (SLO) were not eligible for this
study. SLO was performed after completion of induction
PAC chemotherapy. If macroscopic or microscopic tumour
was not detected in specimens, random peritoneal biopsies
and peritoneal washings were submitted for cytologic
examination. Patients achieving a histologically documented
complete response received no further therapy. Patients
achieving a surgical complete response (microscopic residual
disease) received three additional PAC chemotherapy. Sera
were stored at - 80°C until analysis could be performed.
The tumour response was assessed from the computerised
tomographic (CT) scan, ultrasonographic (US) examination
and routine clinical examinations, with measurement of the
product of the largest diameter and the diameter perpendi-
cular to it. Registration of disease progression requires a
25% or more increase in the size of the existing lesions or the
appearance of clinically measurable new lesions. Disease
regression requires at least a 50% decrease in size for at least
4 weeks for partial response and a disappearance of all
clinical signs ofmalignancy for complete response (Vergote et
al., 1987). Patients who died while on study, yet without
known progressive disease as defined, were considered to
have progression at the date of death.
Determination ofserum CA130 and CA125
Circulating serum CA130 antigen was assayed in sera by
means of a double-determinant sandwich immunoradiometric
assay system developed by using two moABs, 130-22 and
145-9 (Matsuoka, 1988). Serum samples were analysed in
duplicate. The intra-assay and inter-assay coefficients of
variation did not exceed 7.0%. Based on the previous study
(Matsuoka et al., 1987; Inaba et al., 1989), an CA130 antigen
level >35 U ml-' was defined as elevated.
Serum CA125 assays were performed in duplicate using
kits provided by Centocor, Inc (Malvern, PA). A CA125
level of >35 U ml-' was defined as elevated.
The nonparametric Wilcoxon test was used for calculations
of statistical significance.
Results
Characterisation ofantigenic determinant ofCA130 antigen
To investigate the reactivity of each moAB (OC125, 130-22,
or 145-9) with ovarian cancer cell extracts, a microtiter plate
coated with supernatants of sonicated SHIN-3 or HOC-I
cells was incubated with different concentrations (0-8.0jig
ml-') of moABs as described in Figure la,b. OC125, 130-22
and 145-9 reacted with both cancer cell extracts in a dose-
dependent manner. The mode of reactivity resembled each
other. Trypsin treatment of cancer cell extracts abolished the
reactivities of these moABs (Figure 2a,b). To demonstrate
the specificity of moAB binding to HOC-I cell extracts, each
moAB was preincubated with several CA125 antigens, and
then the mixture was added to a microtiter plate. ReactivityCA130 AS A NEW TUMOUR MARKER IN OVARIAN CANCER
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Figure 1 Reactivities of monoclonal antibodies, OC125, 130-22 and 145-9, with cancer cell extracts. A 96 well microtiter plate
coated with supernatants of sonicated SHIN-3 a, or HOC-I cells b, was incubated with different concentrations of moABs
(0-8.01igml-'; 0, OC125; *, 130-22; and E, 145-9).
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Figure 2 Reactivities of monoclonal antibodies, OC125, 130-22 and 145-9, with trypsin-treated cancer cell extracts. A microtiter
plate coated with supernatants of sonicated SHIN-3 a, or HOC-I cells b, was treated with trypsin (0.1%, 1 h, 37C), and then
incubated with different concentrations of moABs (0-8.0pgml-'; *, OC125; *, 130-22; and 0, 145-9).
of endometriotic cyst fluid, menstrual blood, amniotic fluid,
CM from SHIN-3 and HOC-I, and purified CA125 antigen
inhibiting the binding of 130-22 or 145-9 were closely related
to that of OC125 (Figure 3). Meconium solution did not
react with these moABs. CA125 <200 kDa had a significant
inhibitory activity toward the reaction between cancer cell
extracts and antibodies (130-22, 145-9 and OC125). The reac-
tivity of 130-22 or 145-9 to cancer cell extracts was slightly
decreased by CA125 ) 200 kDa, whereas the reactivity of
OC125 was completely inhibited by CA125 >200 kDa.
Comparing the binding of CA125 > 200 kDa to OC125 with
that to 130-22 or 145-9, CA125 > 200 kDa gives rise to more
than 1,000-fold decrease in the reactivity with 130-22 or
145-9 as assessed from the concentration giving 50% inhibi-
tion of the antigen-antibody reaction in our immunoassay
system. The binding of 130-22 or 145-9 was inhibited
specifically by CA125 <200 kDa, indicating that an anti-
genic determinant of CA130 defined by 130-22 and 145-9
were closely related to each other, whereas OC125 recognises
a different epitope on the structurally identical molecule. The
cross-reactivities of these antibodies were investigated by
competitive inhibition assays. In OC125-coated wells, the
binding of HRP-labelled OC125 to the CA125 antigen in
serum of patient with ovarian cancer was not inhibited with
130-22 and 145-9, and that of HRP-labelled 145-9 to the
CA125 antigen was not inhibited with OC125. On the other
hand, in 130-22-coated wells, the binding of HRP-labelled
OC125 to the CA125 antigen was not inhibited with 130-22
and 145-9, and that of HRP-labelled 145-9 to the CA125
antigen was not inhibited with OC125 (Figure 4). We con-
clude that the epitope recognised by 130-22 and 145-9 could
be separated from that recognised by OC125.
CA130 as a new tumour marker in ovarian cancer
We evaluated the significance of tumour marker CA130 in
patients with epithelial ovarian cancer and compared the
levels with those of the CA125 antigen (Table I). One hun-
dred and fifteen (91.3%) of 126 patients with ovarian cancer
were found to have CA130 antigen levels > 35 U ml-'. The
difference in CA130 antigen levels between patients with
ovarian cancer and non-malignant subjects was significant
(P < 0.001). Serum CA125 levels were assayed simultane-
ously and showed 90.5% positivity in ovarian cancer. In the
present study, we noted a higher positiver rate for serum
CA125 than previously reported. Most other publications
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Figure 3 Reactivity of several sources of CA125 antigens with moABs determined by inhibition of binding of each moAB to
HOC-I cell extracts. Each moAB (1.3 igml-') was preincubated with several sources of CA125 antigens (1 h, 23C) and then the
mixture was added to ELISA plate coated with HOC-I cell extract (1 h, 23°C). The following CA125 antigens were used as
competitors: endometriotic cyst fluid (0), menstrual blood (0), amniotic fluid (0), meconium solution (O, as a negative control),
CM from SHIN-3 (A) and HOC-I (A), CA125 antigen purified from CM of HOC-I (V), purified CA125 antigen with molecular
mass of less than 200 kDa (CA125 <200 kDa) (V), purified CA125 antigen with molecular mass of equal or greater than 200 kDa
(CA125 > 200 kDa) (X). Beginning concentrations of CA125 antigens used in our immunoassay system are that: endometriotic
cyst fluid, menstrual blood, amniotic fluid (10% solution in PBS), and meconium solution (1% solution); CM from SHIN-3 and
HOC-I cells (undiluted); CA125 antigen purified from CM of HOC-I, CA125 <200 kDa, and CA125 ) 200 kDa (-0.5 jLgml-').
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Figure 4 The competitive inhibition curves in two-step ELISAs. CA125 antigen was preincubated with each antibody-coated well,
and after washing, various concentrations of unlabelled antibodies were added with either HRP-labelled OC125 or HRP-labelled
145-9. a, In the OC125/OC125 (capture/tracer) sandwich ELISA, HRP-labelled OC125 was incubated together with OC125 (0),
130-22 (A), or 145-9 (A) as a competitor. b, In the 130-22/145-9 (capture/tracer) sandwich ELISA, HRP-labelled 145-9 was
incubated together with OC125 (0), 130-22 (A), or 145-9 (A) as a competitor. c, HRP-labelled 145-9 and OC125-coated wells;
and d, HRP-labelled 145-9 and 130-22-coated wells.CA130 AS A NEW TUMOUR MARKER IN OVARIAN CANCER
Table I Distribution of serum CA130 and CA125 levels
No. of Serum CA130 levels Serum CA125 levels
patients Mean value±s.d. (%)O Mean value±s.d. (%)a
Control 165 12.8± 10.6 (9.1) 18.9 9.8 (9.7)
Benign disease 232
Uterine myoma 63 21.6 ± 23.8 (33.3) 28.3 ± 29.8 (31.7)
Endometriosis 71 51.4± 48.3 (60.6) 70.1 ± 69.3 (62.0)
Ovarian tumour 98 29.6 30.0 (20.4) 35.8 ± 31.0 (22.4)
Ovarian cancer 126
Stage I 45 119.6 106.3 (84.4) 169.3 141.2 (82.2)
Stage II 20 312.4± 281.6 (90.0) 398.0 350.0 (90.0)
Stage III 61 419.3 361.7 (96.7) 547.4 411.9 (96.7)
aPositive rate (%). The cutoff values for serum CA130 and CA125 have been
established as 35 U ml-.
describe an incidence between 80 to 85%. This rather high
percentage of patients with elevated serum levels is probably
not due to the relatively small number ofpre-operative serum
samples available for analysis. Some authors reported that
pre-operative serum CA125 levels were elevated in 90% or
96% (Kivinen et al., 1986; Shilthuis et al., 1987). We assayed
these two antigen levels in sera from patients with benign
gynaecologic disease. CA130 and CA125 was positive in
36.2% and 37.1% of patients with benign disease and in
60.6% and 62.0% of those with endometriosis, respectively.
Like CA125, CA130 also showed a high false-positive rate in
endometriosis in particular. Our data indicated that serum
CA130 levels were closely correlated with serum CA125
levels, demonstrating quite a high correlation coefficient
(r = 0.914). CA130 and CA125 were similar in terms of
sensitivity (91.3% vs 90.5%) and specificity (75.1% vs
74.5%).
Serum CA130 and CA125 levels were assayed simultane-
ously in 119 patients with residual tumour of 2cm or less
after primary cytoreductive surgery. Results of treatment at
SLO are described in Table II. The difference between the
CA130 and CA125 levels in pathological complete responders
and in surgical complete responders was not significant. In
contrast, the differences between these levels in pathological
complete responders and in partial responders were signifi-
cant (P <0.05). Four (10.3%) of 39 patients without residual
disease exceeded 35 U ml-' at SLO. For these patients recur-
rences have not been confirmed for at least 2 years. Six
(18.8%) of 32 surgical complete responders, 14 (46.7%) of 30
partial responders, and all of 18 patients with progressive
disease showed serum CA130 levels ) 35 U ml-'.
Thirty-eight (47.5%) of 80 patients with residual disease
showed levels of CA130 above the cutoff value. Namely, the
sensitivity of CA130 in serum at SLO was 47.5% (38/80) and
the specificity was 89.7% (35/39). The positive and negative
predictive value of an increase in CA130 at SLO was 96.5%
(38/42) and 45.5% (35/77), respectively. CA130 and CA125
yielded essentially identical results in detecting patients with
disease at the time of the SLO. We next examined the time
when the increase in serum CA130 levels occurs during
follow-up (Table III). Sixty-four of 119 patients showed
recurrence during follow-up. In 95.3% (61/64) of the patients
the CA130 increase was correlated to tumour progression or
recurrence.
In 40.6% (26/64) the increase occurred at recurrence, and
in 4.7% (3/64) occurred after recurrence and before death. In
50.0% (32/64) there was an increase before recurrence. In
three patients (4.7%; two patients with mucinous adenocar-
cinoma, stage II and one case with clear cell carcinoma, stage
III) there were no increase in CA130 levels until death. In
one patient with partial response at SLO and in two cases
with progressive disease at SLO, a rise in serum CA130 levels
predated rising serum CA125 levels. Statistical analysis
showed that CA125 and CA130 were similar in terms of the
sensitivity, the specificity, the positive and negative predictive
value at SLO. Also, the simultaneous assay of CA125
showed that similar results were obtained in terms of the
time when the increase in serum CA125 levels occurs during
follow-up. A strong correlation was found between CA130
and CA125, suggesting that the use of both assays does not
further increase the ability to detect microscopic disease at
SLO or during follow-up, since they yielded essentially identi-
cal results.
Discussion
CA130 is a glycoprotein recognised by moABs 130-22 and
145-9. Using these moABs a sensitive sandwich immuno-
radiometric assay for CA130 was developed (Matsuoka,
1988). CA130 is a new tumour marker, different from
CA125, since it has been considered that moABs 130-22 and
OC125 recognise distinct antigenic determinants on the same
antigen (Endo et al., 1988). The antigenic determinant recog-
Table II Serum CA130 and CA125 levels at SLO*
Results of treatment No. of Serum CA130 levels Serum CA125 levels at
at SLO* patients at SLO SLO
Pathological CR** 39 9.8 6.8*** (4)**** 14.7± 9.1*** (4)*****
Surgical CR 32 10.0 ± 8.8 (6) a 16.2 ± 10.2 (6) a
a b a b
Partial response 30 24.9 20.1 (14) 29.5 26.0 (13)
b b
Progressive disease 18 183.4 265.9 (18) 223.9 298.4 (18)
*SLO: Second look operation; **CR: complete response; ***Mean values ± s.d. (U ml);
****No. of patients with CA130 elevation; *****No. of patients with CA125 elevation; a,
P <0.05; b, P <0.01. The present study comprises 119 patients whose residual tumour of 2 cm
or less in size after primary surgery. All patients initially underwent cytoreductive surgery and
were treated with five cycles of combination PAC chemotherapy.
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nised by 130-22 or 145-9 contains a protein moiety because
the reactivity was greatly diminished by trypsin. To clarify
the epitopic structure of CA130, the reactivity of 130-22 or
145-9 with various kinds of CA125 antigens were investigated
by a competitive inhibition assay, which revealed that the
reactivity of 130-22 or 145-9 was completely inhibited by
purified CA125 antigen with molecular mass of less than
200 kDa. Unlike OC125, CA125 antigen with molecular mass
of equal or greater than 200 kDa did not strongly inhibit the
130-22 or 145-9 binding. These facts indicated that antigenic
determinants of CA125 and CA130 could be separated by
.2 u <,,treatment of 6 M urea and heating. Also, the result of the
-.m .m .> >cross-reactivities of OC125, 130-22, and 145-9 by competitive
inhibition assays indicates that the epitope recognised by
*t O'b 0 o _ N o ^130-22 or 145-9 could be separated from that recognised by
a t Q OC125. The CA125 molecule is considered to be composed
of at least two subunits: one subunit reacts with OC125, and
another subunit reacts with 130-22 and 145-9. We do not
have evidence at this time, however, that circulating serum
CA125 antigen produced by cancer cells is the same as that
expressed on their cell surfaces. Nevertheless, moABs 130-22
15 X _ sdand 145-9, that are directed at antigen-expressed deter-
minants other than the CA125 determinants, are important
for a complete understanding of the cell physiology and the
biochemistry of the antigens that expressed the CA125 deter-
3 e= Q X minant (Matsuoka et al., 1987).
Coexpression of these new moABs with OC125 in various
. W) serum samples, support the notion that the new antibodies
.= X <, :: >-O_ o I.-recognise epitopes that are closely associated with those
.0 W X _ > > .recognised by OC125. Serum CA130 levels measured by the
assay system wereclosely correlated with serum CA125 levels
,,O:: m s: > (Matsubara et al., 1989; Inaba et al., 1989), demonstrating
quite a high correlation coefficient. CA130 thus seems to be a
N -< . o- _ o < c useful new tumour marker for ovarian serous cancer and
U- X lung adenocarcinoma (Matsubara et al., 1989; Inaba et al.,
r0 o X ,- r1989). The final result is that the antibodies 130-22/145-9 are rle k x i not superior to OC125 in the detection of epithelial ovarian
o Zj t s w = Ecancer.
_.s: z X o___ ,, a ,, Changes in serum CA125 levels reflect progression or
U 0 t k D. > regression of ovarian cancer more than 90% of the time,
implying that increases in serum CA125 levels reflect disease
progression whereas declines in serum reflect a response to
a X o k _ Q < therapy (Canney et al., 1984; Niloff et al., 1986; Kivinen et
al., 1986; Vergote et al., 1987; Lavin et al., 1987; Mogensen
-= s: Q) =7 2et al., 1990; Buller et al., 1991). Some authors (Rubin et al.,
Cd X 1989; Buller et al., 1991) and we agree that negative CA125 c)C.E z > o ;.= levels after therapy do not imply no microscopic residual
_0 XU5 :w N - > ^ ed Qtumour, although for a given individual the change in CA125
U cd ~~~~level accurately reflects disease status.
In the present study we examined whether our results
a-, enX E s ^°> ^ O u acould give clear indicators as to the clinical value of CA130
O ed > N * > _ °determinations in serum during follow-up of patients with
'e E tu oy N o oo °> =;ovarian cancer. The positive predictive value was high
tn CA 00 ^v ,3.enough in the individual patients for CAl30 to be used as a
single predictor of recurrence. A rise at recurrence seems to
O> be more certain than normalisation at response. There was
no significant differences between serum CA130 levels in
pathological complete responders and those in surgical com-
U v = . ; , plete responders at SLO. Like CA125, normalisation of
K X $ o ,, Q CA130 at response does not imply no microscopic residual
Y . e . ° . disease. It seems that the absence of an increase at recurrence
'. cannot rule out recurrence. Notwithstanding these limita-
: Ge ,x, i) O J z v tions, CA130 changes during follow-up support the evalua-
P A - tion of recurrence and can be used as a monitoring marker in
an individual patient. We conclude that changes in serum
CA130 levels during follow-up are closely correlated with
those in serum CA125 levels, and that clinical significance of
CA130 is almost the same as that of CA125, although these
tumour markers have a separate antigenic determinant.
Buller, R.E. et al. (1991) assumed that there is a relation-
ship between the amount of residual tumour after cytoreduc-
tive surgery and serum CA125 levels, and the decline in
serum CA125 levels in patients with effectively treated
epithelial ovarian cancer follows an exponential regression.
Further prospective clinical trial in a larger series should beCA130 AS A NEW TUMOUR MARKER IN OVARIAN CANCER 243
carried out in order to investigate the clinical usefulness of
CA130 as a follow-up marker in ovarian cancer, and to
determine the threshold of the CA130 test distinguishing
surgical complete responders from patients with residual
disease.
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